Gerardo Miranda-Devora

Soy #Cirujano #Oncólogo Hepato-Pancreato-Biliar. egresado del 👉🏼@incanMX Surgical Oncologist @abccentromedico tweets are my own

[IHPBA @IHPBA]

Underwood et al. found robotic pancreatoduodenectomy increased 1.1% to 10.3% of pancreatic cancer resections in the US between 2010–2020. Outcomes best at high-volume centres reinforcing value of centralisation & structured training as RPD adoption grows 🔗https://t.co/6DoZsvXvF9

[Annals of Hepato-Biliary-Pancreatic Surgery @Journal_AHBPS]

Impact of soft pancreas on pancreaticoduodenectomy outcomes and the development of the preoperative soft pancreas risk score
🌷https://t.co/Lw2GhuF04C
Ann Hepatobiliary Pancreat Surg 2025;29(1). Zofia Czarnecka
#Pancreas #Texture #Pancreaticoduodenectomy #Counselling

[Uttam Laudari @HPBEverestMD]

NEJM: Neoadjuvant GOLP improves EFS in resectable ICC (18 vs 8.7 mo).
High-risk = tumor >5 cm, multi-focal dz, vasc invasion, portal LN+, or ↑CA19-9.
Shift toward biology-first surg. Not routine for all pts.

[Adriana Zucchiatti @zucchiatti_]

Gastric Cancer, A Review
https://t.co/TzcM4JNZHm
#GIpath

[S. George Barreto @sgeorgebarreto]

Advances in our understanding of #pancreaticcancer (#radiology #surgery #medicaloncology #molecularbiology #supportivecare) in the last 50 years for the 50th Anniversary of @WorldJSurg
@Aiims1742 @EileenMOReilly @sahani_dushyant @RZheng8 @CharlesJYeoMD https://t.co/iJj5zNJOFy

[Annals of Gastroenterological Surgery @surgery81261]

📢 HCC management in the systemic therapy era
🔹 Systemic therapy in the ICI era
🔹 Trends in conversion surgery
🔹 Oncological Resectability Criteria (R/BR1/BR2)
A concise review summarizing the current landscape of HCC management by surgeons and hepatologists 📖
Read more ➡️ https://t.co/OdYjcXsBvI
Sohei Satoi (KMU) / Daisuke Asano(Science Tokyo)
#AGSurg #HCC #ICI #ConversionSurgery #SoMe4Surgery @BJSAcademy @me4_so

[Xavier Tello, MD 🇪🇺🇬🇱 @StratCons]

En México, no se regula el acto médico, por eso cualquiera (y con cédula profesional de médico), prescribe patrañas:
1. NO EXISTE la "medicina biológica celular regenerativa".
2. La combinación de esos 4 antibióticos es, en sí mismo, negligencia criminal.
Ahora sí: URGE REGULAR

[Alejandro Macias @doctormacias]

Existen en México más de 300 sitios en donde administran sueros vitaminados intravenosos.
Nadie necesita eso, es charlatanería. Incurren en riesgos absurdos.
https://t.co/VWAf2IhYcC

[Gerardo Miranda-Devora @drgmiranda]

Aterradores los números que se reportan

[Forbes México @Forbes_Mexico]

🚨📈 La cantidad de personas en México sin afiliación a un sistema público de salud pasó de 22.2 millones en 2018 a 47.7 millones en 2024, destaca el CIEP.https://t.co/Pb4cxn5FIg

[AJG - The American Journal of Gastroenterology @AmJGastro]

How I Approach It: Endoscopic Approach to Palliation of Pancreatic Cancer
@CGaineyMD & Todd H. Baron, MD

📕 https://t.co/93STjgPsFm

@EndoTx @MLongMD @JasmohanBajaj

[NEJM @NEJM]

In the phase 3 ATOMIC trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue.  Full trial results and Research Summary: https://t.co/XASue2CCiE

[Gerardo Miranda-Devora @drgmiranda]

Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial https://t.co/fUK5KTSolZ

[Gerardo Miranda-Devora @drgmiranda]

Clinical implications of an intraoperative margin-positive distal bile duct in perihilar cholangiocarcinoma: international multicentre cohort study https://t.co/2LzUWJsz8P

[Diego Barreiro @DBarreiro4]

El FIN de la recaída bioquímica.
El PET con Cobre detecta más del doble de lesiones que el PET con Galio en la recaída post prostatectomia.
En lugar de hablar de recaída bioquímica podremos detectar el sitio de recurrencia y darle al paciente una nueva oportunidad de rescate.

[Gerardo Miranda-Devora @drgmiranda]

Contemporary Adjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasms https://t.co/lNjX4Q6Wrt

[Alejandro Macias @doctormacias]

La FDA aprobó la primera insulina de administración semanal.

La insulina icodec —Awiqli (MR)—demostró reducción de la Hemoglobina glicada A1c superior a la de insulina glargina diaria (HbA1c -1,55% vs -1,35%), y requiere 6 inyecciones menos por semana.

[Gerardo Miranda-Devora @drgmiranda]

Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial https://t.co/fUK5KTSolZ

[EndoCollab™ | GI Endoscopy Community @EndoCollabcom]

ERCP in Whipple anatomy — when the therapeutic scope can't reach the hepaticojejunostomy, what's your next move?

Scope choice, route, and bailout strategy all matter. Altered anatomy cases expose your planning fast.

[Gerardo Miranda-Devora @drgmiranda]

Indocyanine green fluorescence angiography for anastomotic perfusion assessment in colorectal surgery: a systematic review with meta-analysis, meta-regression, and trial sequential analyses - The Lancet Gastroenterology & Hepatology https://t.co/ZrDd702GiY

[Annals of Surgery @AnnalsofSurgery]

In patients with peritoneal surface malignancies, receipt of ≥3 PIPAC treatments was associated with improved survival, particularly when combined with systemic chemotherapy. https://t.co/0UsBUImLbi